Join to View Full Profile
4383 Medical DrFl 3San Antonio, TX 78229
Phone+1 210-593-5700
Fax+1 210-617-7021
Dr. Beeram is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
SUNY Downstate Health Sciences University/Long Island College HospitalResidency, Internal Medicine, 1997 - 2000
Osmania Medical College NTR UHSClass of 1994
Certifications & Licensure
TX State Medical License 2005 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Radiation Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Radiation Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
Clinical Trials
- Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 May 01
- Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2005 Sep 01
- Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01
Publications & Presentations
PubMed
- Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Ana...Keun-Wook Lee, Elena Elimova, Do-Youn Oh, Muralidhar Beeram, Toshihiko Doi
Clinical Cancer Research. 2026-06-01 - 1 citationsImlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advan...Manali Bhave, Komal L Jhaveri, Peter A Kaufman, Philippe Aftimos, Janine Lombard
Breast Cancer Research. 2025-12-21 - 7 citationsZanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results fro...Santiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure
The Lancet. Oncology. 2025-06-01
Press Mentions
Combinations with Abemaciclib Show Long-Term Disease Control in Advanced Breast CancerOctober 19th, 2016
Professional Memberships
- Member
- American Association for Cancer ResearchMember
Other Languages
- Spanish, Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
